Virtual Library
Start Your Search
H. Fu
Author of
-
+
P1.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 224)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.08-036 - Long-Term Survival after Surgical Treatment for Thymic Carcinoma (ID 262)
09:30 - 17:00 | Author(s): H. Fu
- Abstract
Background:
Thymic carcinoma is a type of highly malignant tumor that originates from the thymic epithelium. It is rare and distinct from thymoma. Treatment methods and prognosis of thymic carcinoma remain controversial. To date, three studies with relatively large sample populations have been conducted based respectively on the Surveillance, Epidem iology and End Results database in the United States, the European Society of Thoracic Surgeons, and the Japanese multicenter database. This paper retrospectively analyzes survival data from a large-sample multicenter database in China.
Methods:
The Chinese Alliance for Research of Thymoma (ChART), established in June 2012 in China, constructed a retrospective database of patients with thymic epithelial tumors. This database enrolled 1,930 patients, including 369 with thymic carcinoma. In this study, we analyzed clinical, pathologic and treatment imformation, measured long-term survival rates, and identified relevant prognostic factors.
Results:
Among 369 thymic carcinoma underwented radical intended surgery, 211 underwent R0 resection; 34, R1 resection; and 84, R2 resection. The 3-, 5-, and 10-year survival rates were 78.3%, 67.1%, and 47.9%, respectively. The survival rates of the patients at different Masaoka-Koga stages were significantly different (P ＜ 0.001). The survival rate of the patients who underwent complete resection (R0) was significantly higher than that with incomplete resection (R1/R2)（P < 0.001）. Postoperative chemotherapy did not significantly affect patient survival (P = 0.873). Postoperative radiotherapy significantly improved the overall survival not only of the patients with R1/R2 resection but also of those with stage III/IV disease who underwent R0 resection. Multivariate analyses showed that R0 resection, Masaoka-Koga stage and postoperative radiotherapy were major prognostic factors of overall and disease-free survival. Figure 1
Conclusion:
Surgery remains the primary treatment for thymic carcinoma. R0 resection was the main factor of prognosis. For patients with stage III/IV disease who had undergone R0 resection and all the patients who had undergone R1+R2 resection, postoperative radiotherapy should be administered.
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-025 - The Equivalent Efficacy of Multiple Operations for MPLC and a Single Operation for SPLC (ID 253)
09:30 - 17:00 | Author(s): H. Fu
- Abstract
Background:
The incidence of synchronous and metachronous multiple primary lung cancers (MPLCs) has been increasing recently. The new multidisciplinary classification of lung adenocarcinoma and TNM Classification of Lung Cancer (7[th] edition, 2009), have improved the understanding of MPLC. Most researchers recommend that surgical therapy be actively pursued if the patient’s physical condition and lung function permit it and if a complete cure can be achieved. However, few studies have reported the long-term efficacy of surgical treatment for MPLC, which we explored in this study.
Methods:
One thousand two houndred and ningty Lung cancer patients from a prospectively maintained database, treated by a single surgeon group between January 2000 and July 2013, at Beijing Cancer Hospital, Peking University, were reviewed. We retrospectively analyzed the clinical data of 31 patients diagnosed with MPLC out of 1290 lung cancer patients, focusing on long-term survival.
Results:
MPLC patients accounted for 2.4% (31/1290) of the patient cohort: 27 had synchronous MPLC (87.1%) and 4 had metachronous MPLC (12.9%). The 1- and 3-year postoperative survival rates were 100% and 73.5%, respectively. On stratification according to TNM stage, the 1- and 3-year survival rates of patients with stage I cancer (20 patients) were 100% and 77.8%, respectively, not statistically significant with those for the entire cohort (1290 patients; 95.4% and 80.5%, respectively, p=0.876).
Conclusion:
When the patient’s physical condition and tumor-related factors permit it, surgery should be the first choice of treatment for MPLC; it is associated with an equivalent efficacy to that of surgery for single primary lung cancer.
